Positives:
-Staff costs down 17% from Q1
-Product manufacturing down 18% from Q1, good work Scott Bliss.
-Nice to see they have finally split "other working capital" into product manufacturing and "admin/corps costs", which slightly dropped by 21k from Q1 to Q2. Even with new head office opening in US.
- CardioCel sales increased by 19% over Q1 (1.6m to 1.9m)
- H2 expected to be stronger than H1, based on history. Will smash $21m forecast.
Negatives:
-Increased lag between sales and cash receipts, expect to see a large receivable balance at 31 Dec due to US financial year end.
Watch out for the tree shake today.
Ann: Appendix 4C - quarterly, page-27
-
- There are more pages in this discussion • 221 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.65 |
Change
-0.350(2.33%) |
Mkt cap ! $309.6M | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.94 | $14.25 | $1.266M | 86.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 126 | $14.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.65 | 99 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |